137 related articles for article (PubMed ID: 3289511)
1. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.
Mackworth-Young CG; David J; Morgan SH; Hughes GR
Ann Rheum Dis; 1988 Jun; 47(6):496-502. PubMed ID: 3289511
[TBL] [Abstract][Full Text] [Related]
2. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.
Edwards JC; Snaith ML; Isenberg DA
Ann Rheum Dis; 1987 Oct; 46(10):773-6. PubMed ID: 3318723
[TBL] [Abstract][Full Text] [Related]
3. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus.
Parker BJ; Bruce IN
Lupus; 2007; 16(6):387-93. PubMed ID: 17664228
[TBL] [Abstract][Full Text] [Related]
4. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.
Lancet; 1993 Mar; 341(8845):586-90. PubMed ID: 8094828
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF; Hahn BH; Tsokos GC; Wagner CL; Lipsky P; Touma Z; Werth VP; Gordon RM; Zhou B; Hsu B; Chevrier M; Triebel M; Jordan JL; Rose S
Lancet; 2018 Oct; 392(10155):1330-1339. PubMed ID: 30249507
[TBL] [Abstract][Full Text] [Related]
6. Monthly pulses of methylprednisolone in SLE nephritis.
Liebling MR; McLaughlin K; Boonsue S; Kasdin J; Barnett EV
J Rheumatol; 1982; 9(4):543-8. PubMed ID: 7131454
[TBL] [Abstract][Full Text] [Related]
7. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytopenia in a case of systemic lupus erythematosus: repeated administration of 'pulse' methyl prednisolone.
Mackworth-Young CG; Walport MJ; Hughes GR
Br J Rheumatol; 1984 Nov; 23(4):298-300. PubMed ID: 6487937
[TBL] [Abstract][Full Text] [Related]
9. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus.
Baca V; Lavalle C; García R; Catalán T; Sauceda JM; Sánchez G; Martínez I; Ramírez ML; Márquez LM; Rojas JC
J Rheumatol; 1999 Feb; 26(2):432-9. PubMed ID: 9972981
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
[TBL] [Abstract][Full Text] [Related]
11. Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation.
Ballou SP; Khan MA; Kushner I
J Rheumatol; 1985 Oct; 12(5):944-8. PubMed ID: 3910835
[TBL] [Abstract][Full Text] [Related]
12. High-dose, pulse intravenous methylprednisolone enhances Fc gamma receptor-mediated mononuclear phagocyte function in systemic lupus erythematosus.
Salmon JE; Kapur S; Meryhew NL; Runquist OA; Kimberly RP
Arthritis Rheum; 1989 Jun; 32(6):717-25. PubMed ID: 2525382
[TBL] [Abstract][Full Text] [Related]
13. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study.
Lindberg C; Andersen O; Lefvert AK
Acta Neurol Scand; 1998 Jun; 97(6):370-3. PubMed ID: 9669469
[TBL] [Abstract][Full Text] [Related]
14. Intravenous methylprednisolone in the treatment of systemic lupus erythematosus.
Mackworth-Young CG; Morgan SH; Hughes GR
Scand J Rheumatol Suppl; 1984; 54():16-8. PubMed ID: 6592750
[No Abstract] [Full Text] [Related]
15. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials.
Liu S; Liu X; Chen S; Xiao Y; Zhuang W
PLoS One; 2017; 12(11):e0188644. PubMed ID: 29176905
[TBL] [Abstract][Full Text] [Related]
16. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
Grau-López L; Teniente-Serra A; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Martínez-Cáceres EM; Ramo-Tello C
Mult Scler; 2015 Apr; 21(5):646-50. PubMed ID: 25145693
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
18. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.
Trevisani VF; Castro AA; Neves Neto JF; Atallah AN
Cochrane Database Syst Rev; 2006 Apr; (2):CD002265. PubMed ID: 16625558
[TBL] [Abstract][Full Text] [Related]
19. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus.
Massardo L; Jacobelli S; Leissner M; González M; Villarroel L; Rivero S
Lupus; 1992 Dec; 1(6):401-5. PubMed ID: 1304409
[TBL] [Abstract][Full Text] [Related]
20. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
